CHIP Presents at Society for Immunotherapy of Cancer
CHIP Associate Director Theresa Walunas, PhD, is presenting at the Society for Immunotherapy of Cancer (SITC) conference in National Harbor, Maryland, this week. The poster is called, “Identification of Patients who Received Checkpoint Therapy in a Regional Integrated Health Record Data Network to Explore Immunotoxic Events in a Real World Setting.”
Immune checkpoint inhibitor (ICI) therapy is a form of immunotherapy used widely as a standard of care for many cancers. Immune-related adverse events (irAE) occur in over 80% of patients receiving immune checkpoint inhibitors. Currently, most data about the incidence of irAEs comes from clinical trials with restrictive eligibility requirements. With the widespread use of ICI therapy, it is important to assess incidence of irAEs in a general patient population.
The research team identified three key findings:
- A large cohort of cancer patients who have received immune checkpoint inhibitor (ICI) therapy can be identified in an integrated medical record dataset.
- The identified population is highly diverse, representing a wide range of ages, a number of races, both sexes, and all cancer types approved for immune checkpoint inhibitor therapy as of 2018.
- This cohort will be an effective foundation on which to explore the incidence of immune-related adverse events (irAE), particularly rare irAE that require large sample sizes to investigate.
The research team included Northwestern Medicine Faculty Carlos Galvez, MD, Saya Jacob, MD, Jeffrey Sosman, MD, and CHIP Director Abel Kho, MD, MS.
To learn more, visit the SITC 2019 website.